Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 89

1.

Into the third decade: eleventh ISABS Conference on Forensic and Anthropological Genetics and Mayo Clinic Lectures in Individualized Medicine.

Vuk-Pavlović S, Schanfield M, Primorac D.

Croat Med J. 2019 Jun 13;60(3):189-190. No abstract available.

2.
3.

Effects of oxygen on the antigenic landscape of prostate cancer cells.

Ma T, Schreiber CA, Knutson GJ, Khattouti AE, Sakiyama MJ, Hassan M, Charlesworth MC, Madden BJ, Zhou X, Vuk-Pavlović S, Gomez CR.

BMC Res Notes. 2015 Nov 18;8:687. doi: 10.1186/s13104-015-1633-7.

4.

Prognostic value of discs large homolog 7 transcript levels in prostate cancer.

Gomez CR, Kosari F, Munz JM, Schreiber CA, Knutson GJ, Ida CM, El Khattouti A, Karnes RJ, Cheville JC, Vasmatzis G, Vuk-Pavlović S.

PLoS One. 2013 Dec 9;8(12):e82833. doi: 10.1371/journal.pone.0082833. eCollection 2013.

5.
6.

Personalizing immunotherapy: Balancing predictability and precision.

Agur Z, Vuk-Pavlović S.

Oncoimmunology. 2012 Oct 1;1(7):1169-1171.

7.

Reconsidering the paradigm of cancer immunotherapy by computationally aided real-time personalization.

Kogan Y, Halevi-Tobias K, Elishmereni M, Vuk-Pavlović S, Agur Z.

Cancer Res. 2012 May 1;72(9):2218-27. doi: 10.1158/0008-5472.CAN-11-4166. Epub 2012 Mar 15.

8.

Age-dependent response of murine female bone marrow cells to hyperbaric oxygen.

Gomez CR, Knutson GJ, Clifton KB, Schreiber CA, Vuk-Pavlović S.

Biogerontology. 2012 Jun;13(3):287-97. doi: 10.1007/s10522-012-9373-8. Epub 2012 Jan 24.

9.

Mathematical modeling in immunotherapy of cancer: personalizing clinical trials.

Agur Z, Vuk-Pavlović S.

Mol Ther. 2012 Jan;20(1):1-2. doi: 10.1038/mt.2011.272. No abstract available.

10.

Biomathematical modeling and cancer immunotherapy: report of the workshop held at Bol, Island of Brač, Croatia, 20-21 June 2011.

Vuk-Pavlović S.

Cytotherapy. 2012 Feb;14(2):144-6. doi: 10.3109/14653249.2011.623694. Epub 2011 Oct 24.

PMID:
22017451
11.

Predicting outcomes of prostate cancer immunotherapy by personalized mathematical models.

Kronik N, Kogan Y, Elishmereni M, Halevi-Tobias K, Vuk-Pavlović S, Agur Z.

PLoS One. 2010 Dec 8;5(12):e15482. doi: 10.1371/journal.pone.0015482.

12.

Immunosuppressive CD14+HLA-DRlow/- monocytes in prostate cancer.

Vuk-Pavlović S, Bulur PA, Lin Y, Qin R, Szumlanski CL, Zhao X, Dietz AB.

Prostate. 2010 Mar 1;70(4):443-55. doi: 10.1002/pros.21078.

13.

Metastatic malignant melanoma.

Markovic SN, Erickson LA, Flotte TJ, Kottschade LA, McWilliams RR, Jakub JW, Farley DR, Tran NV, Schild SE, Olivier KR, Vuk-Pavlovic S, Sekulic A, Weenig RH, Pulido JS, Quevedo JF, Vile RG, Wiseman GA, Stoian I, Pittelkow MR; Melanoma Study Group of the Mayo Clinic Cancer Center.

G Ital Dermatol Venereol. 2009 Feb;144(1):1-26. Review.

PMID:
19218908
14.

Dendritic cell microvilli: a novel membrane structure associated with the multifocal synapse and T-cell clustering.

Fisher PJ, Bulur PA, Vuk-Pavlovic S, Prendergast FG, Dietz AB.

Blood. 2008 Dec 15;112(13):5037-45. doi: 10.1182/blood-2008-04-149526. Epub 2008 Sep 19.

15.

Immune cells in the human choroid.

Ezzat MK, Hann CR, Vuk-Pavlovic S, Pulido JS.

Br J Ophthalmol. 2008 Jul;92(7):976-80. doi: 10.1136/bjo.2007.129742.

PMID:
18577650
16.

Rebuilding immunity in cancer patients.

Vuk-Pavlovic S.

Blood Cells Mol Dis. 2008 Jan-Feb;40(1):94-100. Epub 2007 Sep 10. Review.

17.

Plasmacytoid dendritic cells in inflamed muscle of patients with juvenile dermatomyositis.

López de Padilla CM, Vallejo AN, McNallan KT, Vehe R, Smith SA, Dietz AB, Vuk-Pavlovic S, Reed AM.

Arthritis Rheum. 2007 May;56(5):1658-68.

18.

A novel source of viable peripheral blood mononuclear cells from leukoreduction system chambers.

Dietz AB, Bulur PA, Emery RL, Winters JL, Epps DE, Zubair AC, Vuk-Pavlović S.

Transfusion. 2006 Dec;46(12):2083-9.

PMID:
17176319
19.

Preparing clinical-grade myeloid dendritic cells by electroporation-mediated transfection of in vitro amplified tumor-derived mRNA and safety testing in stage IV malignant melanoma.

Markovic SN, Dietz AB, Greiner CW, Maas ML, Butler GW, Padley DJ, Bulur PA, Allred JB, Creagan ET, Ingle JN, Gastineau DA, Vuk-Pavlovic S.

J Transl Med. 2006 Aug 15;4:35.

20.

Testing the safety of clinical-grade mature autologous myeloid DC in a phase I clinical immunotherapy trial of CML.

Litzow MR, Dietz AB, Bulur PA, Butler GW, Gastineau DA, Hoering A, Fink SR, Letendre L, Padley DJ, Paternoster SF, Tefferi A, Vuk-Pavlović S.

Cytotherapy. 2006;8(3):290-8.

PMID:
16793737
21.

Integrating new countries into the European Research Area. Croatian reflections on joining the European Union.

Pavelić K, Primorac D, Vuk-Pavlović S.

EMBO Rep. 2006 May;7(5):458-62. No abstract available.

22.

Clinical-grade manufacturing of DC from CD14+ precursors: experience from phase I clinical trials in CML and malignant melanoma.

Dietz AB, Padley DJ, Butler GW, Maas ML, Greiner CW, Gastineau DA, Vuk-Pavlović S.

Cytotherapy. 2004;6(6):563-70.

PMID:
15773024
23.

Modeling positive regulatory feedbacks in cell-cell interactions.

Bajzer Z, Vuk-Pavlović S.

Biosystems. 2005 Apr;80(1):1-10.

PMID:
15740830
24.

Fourth International Workshop on Haploidentical Transplants, Naples, Italy, July 8-10, 2004.

Aversa F, Berneman ZN, Locatelli F, Martelli MF, Reisner Y, Tabilio A, Velardi A, Vuk-Pavlovic S.

Blood Cells Mol Dis. 2004 Nov-Dec;33(3):159-75.

PMID:
15580686
25.

Immunotherapy (APC8015, Provenge) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: a Phase 2 trial.

Burch PA, Croghan GA, Gastineau DA, Jones LA, Kaur JS, Kylstra JW, Richardson RL, Valone FH, Vuk-Pavlović S.

Prostate. 2004 Aug 1;60(3):197-204.

PMID:
15176049
26.

Imatinib mesylate inhibits T-cell proliferation in vitro and delayed-type hypersensitivity in vivo.

Dietz AB, Souan L, Knutson GJ, Bulur PA, Litzow MR, Vuk-Pavlovic S.

Blood. 2004 Aug 15;104(4):1094-9. Epub 2004 Apr 20.

27.

Cloning the cDNA for murine U2 snRNP-A' gene and its differential expression in lymphocyte development.

Antica M, Kusic B, Hranilovic D, Dietz AB, Vuk-Pavlovic S.

Immunol Lett. 2002 Jul 3;82(3):217-23.

PMID:
12036604
28.

Transgenic interleukin 2 secreted by CML dendritic cells stimulates autologous T(H)1 T cells.

Dietz AB, Litzow MR, Bulur PA, Vuk-Pavlović S.

Cytotherapy. 2001;3(2):97-105.

PMID:
12028832
29.

Immunomagnetic separation reagents as markers in electron microscopy.

Fisher PJ, Springett MJ, Dietz AB, Bulur PA, Vuk-Pavlović S.

J Immunol Methods. 2002 Apr 1;262(1-2):95-101.

PMID:
11983222
30.

Maturation of human dendritic cells as sulfasalazine target.

Matasić R, Dietz AB, Vuk-Pavlović S.

Croat Med J. 2001 Aug;42(4):440-5.

31.

Engineering dendritic cell grafts for clinical trials in cellular immunotherapy of cancer: example of chronic myelogenous leukemia.

Dietz AB, Litzow MR, Gastineau DA, Vuk-Pavlović S.

Croat Med J. 2001 Aug;42(4):428-35. Review.

32.
33.

Mature myeloid dendritic cells for clinical use prepared from CD14+ cells isolated by immunomagnetic adsorption.

Padley DJ, Dietz AB, Gastineau DA, Vuk-Pavlovic S.

J Hematother Stem Cell Res. 2001 Jun;10(3):427-9. No abstract available.

PMID:
11454318
34.

Maturation of dendritic cells infected by recombinant adenovirus can be delayed without impact on transgene expression.

Dietz AB, Bulur PA, Brown CA, Pankratz VS, Vuk-Pavlovic S.

Gene Ther. 2001 Mar;8(5):419-23.

35.

Cyclooxygenase-independent inhibition of dendritic cell maturation by aspirin.

Matasic R, Dietz AB, Vuk-Pavlovic S.

Immunology. 2000 Sep;101(1):53-60.

36.

Maturation of human monocyte-derived dendritic cells studied by microarray hybridization.

Dietz AB, Bulur PA, Knutson GJ, Matasić R, Vuk-Pavlović S.

Biochem Biophys Res Commun. 2000 Sep 7;275(3):731-8.

PMID:
10973791
37.

Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer.

Burch PA, Breen JK, Buckner JC, Gastineau DA, Kaur JA, Laus RL, Padley DJ, Peshwa MV, Pitot HC, Richardson RL, Smits BJ, Sopapan P, Strang G, Valone FH, Vuk-Pavlović S.

Clin Cancer Res. 2000 Jun;6(6):2175-82.

38.

Joining together to combat poverty.

Heath I, Haines A, Malenica Z, Oulton JA, Leopando Z, Kaseje D, Addington WW, Giscard D'Estaing O, Tumwine JK, Koivusalo M, Biscoe G, Nickson P, Marusić M, Vuk Pavlović S.

Croat Med J. 2000 Mar;41(1):28-31.

39.

Optimizing preparation of normal dendritic cells and bcr-abl+ mature dendritic cells derived from immunomagnetically purified CD14+ cells.

Dietz AB, Bulur PA, Erickson MR, Wettstein PJ, Litzow MR, Wyatt WA, Dewald GW, Tefferi A, Pankratz VS, Vuk-Pavlović S.

J Hematother Stem Cell Res. 2000 Feb;9(1):95-101.

PMID:
10738977
40.

Dexamethasone inhibits dendritic cell maturation by redirecting differentiation of a subset of cells.

Matasić R, Dietz AB, Vuk-Pavlović S.

J Leukoc Biol. 1999 Dec;66(6):909-14.

PMID:
10614771
41.
42.

Recombinant human thrombopoietin in combination with granulocyte colony-stimulating factor enhances mobilization of peripheral blood progenitor cells, increases peripheral blood platelet concentration, and accelerates hematopoietic recovery following high-dose chemotherapy.

Somlo G, Sniecinski I, ter Veer A, Longmate J, Knutson G, Vuk-Pavlovic S, Bhatia R, Chow W, Leong L, Morgan R, Margolin K, Raschko J, Shibata S, Tetef M, Yen Y, Forman S, Jones D, Ashby M, Fyfe G, Hellmann S, Doroshow JH.

Blood. 1999 May 1;93(9):2798-806.

43.

High efficiency adenovirus-mediated gene transfer to human dendritic cells.

Dietz AB, Vuk-Pavlović S.

Blood. 1998 Jan 15;91(2):392-8.

44.

Nitrogen-15 NMR chemical shifts in oligopeptides coordinated to cobalt(III).

Juranić N, Vuk-Pavlović S, Nikolić AT, Chen TB, Macura S.

J Inorg Biochem. 1996 May 1;62(2):117-26.

PMID:
8729798
45.

Expression of somatostatin receptor subtypes in breast carcinoma, carcinoid tumor, and renal cell carcinoma.

Vikić-Topić S, Raisch KP, Kvols LK, Vuk-Pavlović S.

J Clin Endocrinol Metab. 1995 Oct;80(10):2974-9.

PMID:
7559883
46.
47.

Tumor growth in vivo and as multicellular spheroids compared by mathematical models.

Marusić M, Bajzer Z, Vuk-Pavlović S, Freyer JP.

Bull Math Biol. 1994 Jul;56(4):617-31.

PMID:
8054889
48.

Analysis of growth of multicellular tumour spheroids by mathematical models.

Marusić M, Bajzer Z, Freyer JP, Vuk-Pavlović S.

Cell Prolif. 1994 Feb;27(2):73-94.

PMID:
10465028
49.

EndoCyte 1.2: An improved algorithm for quantitative analysis of receptor-mediated endocytosis.

Zelić A, Bajzer Z, Vuk-Pavlović S.

Int J Biomed Comput. 1993 Nov;33(3-4):241-8.

PMID:
8307655
50.

Insulin-like growth factor-I is a serum component stimulating growth of human neuroblastoma.

Burke TW, Vuk-Pavlović S.

In Vitro Cell Dev Biol Anim. 1993 May;29A(5):391-4.

PMID:
8314733

Supplemental Content

Loading ...
Support Center